Hirano Patricia C 4

What Happened
Patricia C. Hirano, Senior Vice President, Regulatory Affairs at Soleno Therapeutics (SLNO), received equity awards on 2026-01-21 totaling 22,300 share-equivalents. The filing reports two awards: 10,400 restricted stock units (RSUs) and 11,900 derivative RSU/option-type awards. The reported acquisition price for both grants is $0.00 (typical for RSU grants); no cash changed hands at grant.

Key Details

• Transaction date: 2026-01-21; Form 4 filed 2026-01-23. Filing appears timely.
• Awards: 10,400 RSUs (F1) + 11,900 derivative RSU/award (F2/F3) = 22,300 total. Reported price: $0.00; reported value: $0.
• Vesting: F1 — the 10,400 RSUs vest 100% on December 15, 2027, conditioned on continued service. F2/F3 — the 11,900 derivative awards are RSU/award-type and subject to their applicable vesting schedule; one referenced schedule vests 1/48th beginning Feb 1, 2026 and monthly thereafter, subject to continued service.
• Shares owned after transaction: not stated in the provided filing data.
• Officer title: Senior Vice President, Regulatory Affairs (per remarks).
• Filing status: Not marked late (filed within standard Form 4 time frame).

Context
These are compensation awards (RSUs/derivative awards), not open-market purchases or sales, so they reflect company compensation rather than a direct buy/sell signal. RSUs represent a contingent right to receive shares upon vesting; no immediate shares were issued or sold at the grant date. The monthly/long-term vesting conditions mean the awards vest over time and depend on continued service.